So far, insulin Icodec has been demonstrated to be slightly better than daily administered basal analogs in terms of glucose control and the chance to achieve targeted glucose levels without a relevant gain in the risk of hypoglycemia in T2D. The gene discussed is INS; the disease is Hypoglycemia.